TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases

Journal of Gastroenterology

Volumn 49, Issue 6, 2014, Pages 971-981

  Matsuzaki, Koichi ^a   Seki, Toshihito ^a   Okazaki, Kazuichi ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarkers; Hepatic carcinogenesis; Liver fibrosis; Smad; TGF

Indexed keywords

BIOLOGICAL MARKER; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIVIRAL THERAPY; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL DAMAGE; CELL TYPE; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; FIBROGENESIS; HEPATITIS VIRUS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; VIRUS INFECTION; CHRONIC DISEASE; HUMAN; LIVER TUMOR; METABOLISM;

CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84902360236     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0910-2     Document Type: Review

References (88)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-73.
2. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-29. (Pubitemid 40364823)
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52.
4. Tanaka Y, Kurbanov F, Mano S, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130: 703-14. (Pubitemid 43374521)
5. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7:425-36.
6. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-35.
7. Matsuzaki K. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res. 2012;347:225-43.
8. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-24. (Pubitemid 30171890)
9. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174-81. (Pubitemid 29364999)
10. Morgan TR, Ghany MG, Kim HY, HALT-C Trial Group, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-44.
11. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186-91. (Pubitemid 46680721)
12. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339-46. (Pubitemid 35154440)
13. Moses HL, Serra R. Regulation of differentiation by TGF-β. Curr Opin Genet Dev. 1996;6:581-6.
14. Massagué J. TGF-β signalling in context. Nat Rev Mol Cell Biol. 2012;13:616-30.
15. Matsuzaki K, Date M, Furukawa F, et al. Autocrine stimulatory mechanism by transforming growth factor β in human hepatocellular carcinoma. Cancer Res. 2000;60:1394-402. (Pubitemid 30152013)
16. Matsuzaki K, Date M, Furukawa F, et al. Regulatory mechanisms for transforming growth factor β as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of Smads in its growth. Hepatology. 2000;32:218-27. (Pubitemid 30614653)
17. Meindl-Beinker NM, Matsuzaki K, Dooley S. TGF-β signaling in onset and progression of hepatocellular carcinoma. Dig Dis. 2012;30:514-23.
18. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, editors. Peptide growth factors and their receptors. Berlin: Springer; 1990. p. 419-72.
19. Heldin CH, Miyazono K, ten Dijke P. TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390: 465-71. (Pubitemid 28013118)
20. Derynck R, Miyazono K. The TGF-β signaling. New York: Cold Spring Harbor Laboratory Press; 2008.
21. Matsuura I, Denissova NG, Wang G, et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004;430:226-31. (Pubitemid 38902433)
22. Wang G, Matsuura I, He D, et al. Transforming growth factor-β- inducible phosphorylation of Smad3. J Biol Chem. 2009;284:9663-73.
23. Matsuzaki K, Kitano C, Murata M, et al. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-b signal in later stages of human colorectal cancer. Cancer Res. 2009;69:5321-30.
24. Alarcón C, Zaromytidou AI, Xi Q, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-βpathways. Cell. 2009;139:757-69.
25. Gao S, Alarcón C, Sapkota G, et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-b signaling. Mol Cell. 2009;36:457-68.
26. Matsuura I, Wang G, He D, et al. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry. 2005;44:12546-53.
27. Mori S, Matsuzaki K, Yoshida K, et al. TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene. 2004;23:7416-29. (Pubitemid 39382144)
28. Sekimoto G, Matsuzaki K, Yoshida K, et al. Reversible Smaddependent signaling between tumor suppression and oncogenesis. Cancer Res. 2007;67:5090-6. (Pubitemid 46997243)
29. van der Velden JL, Alarcón JF, Guala AS, et al. c-Jun N-terminal kinase 1 promotes TGF-β1-induced epithelial to mesenchymaltransition via control of linker phosphorylation and transcriptional activity of Smad3. Am J Respir Cell Mol Biol. 2011;44:571-81.
30. Saito A, Suzuki HI, Horie M, et al. An integrated expression profiling reveals target genes of TGF-β and TNF-α possibly mediated by micro RNAs in lung cancer cells. PLoS ONE. 2013;8:e56587.
31. Yumoto K, Thomas PS, Lane J, et al. TGF-β-activated kinase 1(Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crestderived cells. J Biol Chem. 2013;288:13467-80.
32. Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology. 2003;38:879-89. (Pubitemid 37221671)
33. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 map kinase pathways in transforming growth factor β mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem. 2005;280:1024-36.
34. Millet C, Yamashita M, Heller M, et al. A negative feedback control of transforming growth factor-β signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J Biol Chem. 2009;284:19808-16.
35. Guo X, Ramirez A, Waddell DS, et al. Axin and GSK3-b control Smad3 protein stability and modulate TGF-β signaling. Genes Dev. 2008;22:106-20.
36. Abushahba W, Olabisi OO, Jeong BS, et al. Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. PLoS ONE. 2012;7:e47312.
37. Matsuzaki K. Smad phospho-isoforms direct context-dependent TGF-b signaling. Cytokine Growth Factor Rev. 2013;24:385-99.
38. Liu F. Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 2006;17:9-17. (Pubitemid 43117512)
39. Wrighton KH, Lin X, Feng X-H. Phospho-control of TGF-βsuperfamily signaling. Cell Res. 2009;19:8-20.
40. Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis. 2011;32:1578-88.
41. Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res. 2009;19:128-39.
42. Moustakas A, Heldin CH. Non-Smad TGF-β signals. J Cell Sci. 2005;118:3573-84.
43. Yamanaka M, Shegogue D, Pei H, et al. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-β and mediates TIMP-1 up-regulation. J Biol Chem. 2004;279:53994-4001. (Pubitemid 40053131)
44. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 2005;102:13909-14. (Pubitemid 41377677)
45. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol. 2002;4:487-94. (Pubitemid 34752433)
46. Ikushima H, Todo T, Ino Y, et al. Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009;5:504-14.
47. Yoshida K, Matsuzaki K, Mori S, et al. Transforming growth factor-β and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol. 2005;166:1029-39. (Pubitemid 40524428)
48. Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213:286-300. (Pubitemid 47509705)
49. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99.
50. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 2007;46:48-57. (Pubitemid 47171920)
51. Murata M, Matsuzaki K, Yoshida K, et al. Hepatitis B virus X protein shifts human hepatic TGF-β signaling from tumor-suppression to oncogenesis in early chronic hepatitis B. Hepatology. 2009;49:1203-17.
52. Nagata H, Hatano E, Tada M, et al. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology. 2009;49:1944-53.
53. Kawamata S, Matsuzaki K, Murata M, et al. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis. 2011;17:683-95.
54. Date M, Matsuzaki K, Matsushita M, et al. Differential expression of transforming growth factor-β and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl4 administration. J Hepatol. 1998;28:572-81. (Pubitemid 28167994)
55. Date M, Matsuzaki K, Matsushita M, et al. Modulation of transforming growth factor β function in hepatocytes and hepatic stellate cells in rat liver injury. Gut. 2000;46:719-24. (Pubitemid 30305793)
56. Kaji K, Yoshiji H, Ikenaka Y, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2013 (Epub ahead of print).
57. Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, et al. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress. J Gastroenterol. 2013;48:222-37.
58. Pinzani M, Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol. 2010;4: 459-72.
59. Kluwe J, Pradere JP, Gwak GY, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology. 2010;138:347-59.
60. Mu X, Lin S, Yang J, et al. TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells. PLoS ONE. 2013;8:e63436.
61. Glick AB, Weinberg WC, Wu IH, et al. Transforming growth factor β 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res. 1996;56:3645-50. (Pubitemid 26272005)
62. Tremain R, Marko M, Kinnimulki V, et al. Defects in TGF-β signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene. 2000;19:1698-709. (Pubitemid 30200972)
63. Yang H, Kyo S, Takatura M, et al. Autocrine transforming growth factor β suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth Differ. 2001;12:119-27. (Pubitemid 32194901)
64. Weinberg RA. The biology of cancer. New York: Garlang Science; 2007.
65. Yamaguchi T, Matsuzaki K, Inokuchi R, et al. Phosphorylated Smad2 and Smad3 signaling: shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res. 2013 (Epub ahead of print).
66. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996;97:232-7. (Pubitemid 26021713)
67. Hu PF, Chen H, Zhong W, et al. Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol. 2009;51:102-13.
68. Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer. 1994;73:2275-9. (Pubitemid 24129108)
69. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006;26:1029-39. (Pubitemid 44541743)
70. Sugano Y, Matsuzaki K, Tahashi Y, et al. Distortion of autocrine transforming growth factor β signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene. 2003;22:2309-21. (Pubitemid 36566786)
71. Hidaka H, Nakazawa T, Shibuya A, et al. Effects of 1-year administration of olmesartan on portal pressure and TGF-b1 in selected patients with cirrhosis: a randomized controlled trial. J Gastroenterol. 2011;46:1316-23.
72. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
73. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73. (Pubitemid 43042691)
74. Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127:S56-61. (Pubitemid 39423370)
75. Kim CM, Koike K, Saito I, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351:317-20. (Pubitemid 21896589)
76. Madden CR, Finegold MJ, Slagle BL. Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol. 2001;75:3851-8. (Pubitemid 32246394)
77. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065-7. (Pubitemid 28417341)
78. Szabo G, Chang S, Dolganiuc A. Altered innate immunity in chronic hepatitis C infection: cause or effect? Hepatology. 2007;46:1279-90. (Pubitemid 350144792)
79. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. (Pubitemid 36019639)
80. Hamajima H, Ozaki I, Zhang H, et al. Modulation of the transforming growth factor-β1-induced Smad phosphorylation by theextracellular matrix receptor b1-integrin. Int J Oncol.2009;35:1441-7.
81. Chen D, Lin Q, Box N, et al. SKI knockdown inhibits human melanoma tumor growth in vivo. Pigment Cell Melanoma Res. 2009;22:761-72.
82. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105-17. (Pubitemid 36055344)
83. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-51. (Pubitemid 44958517)
84. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-93.
85. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410-26.
86. Eun JR, Lee HJ, Kim TN, et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 2010;53:118-25.
87. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109-16.
88. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006;25:3778-86. (Pubitemid 43980473)